Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.

Abstract

Affiliations of authors: Department of Clinical Epidemiology, Bremen Institute for Prevention Research and Social Medicine, Bremen, Germany (RTM, JH); Department of Health Economy and Management, Bielefeld University, Bielefeld, Germany (OD); Clinic for Gynecology, Gynecologic Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin and Mitte, Berlin, Germany (AK); Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands (MK); Centre for Infectious Disease Control, Epidemiology and Surveillance Unit, RIVM, Bilthoven, the Netherlands (MK).

DOI: 10.1093/jnci/djr517

Cite this paper

@article{Mikolajczyk2012ReES, title={Re: Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections.}, author={Rafael T. Mikolajczyk and Johannes Horn and Oliver Damm and Andreas Kaufmann and Mirjam Kretzschmar}, journal={Journal of the National Cancer Institute}, year={2012}, volume={104 2}, pages={163; author reply 163-4} }